# Inhaled Nebulized Tobramycin in Non-cystic Fibrosis Bronchiectasis

> **NCT02657473** · PHASE2,PHASE3 · COMPLETED · sponsor: **Medical Center Alkmaar** · enrollment: 58 (actual)

## Conditions studied

- Non-CF Bronchiectasis

## Interventions

- **DRUG:** tobramycin inhalation solution
- **DRUG:** Saline 0.9% inhalation solution

## Key facts

- **NCT ID:** NCT02657473
- **Lead sponsor:** Medical Center Alkmaar
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-13
- **Primary completion:** 2019-12-13
- **Final completion:** 2019-12-13
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2019-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02657473

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02657473, "Inhaled Nebulized Tobramycin in Non-cystic Fibrosis Bronchiectasis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02657473. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*